Author:
Tageja Nishant,Korde Neha,Kazandjian Dickran,Panch Sandhya,Manasanch Elisabet,Bhutani Manisha,Kwok Mary,Mailankody Sham,Yuan Constance,Stetler-Stevenson Maryalice,Leitman Susan F.,Sportes Claude,Landgren Ola
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Reference11 articles.
1. Kay NE, Leong T, Kyle RA, Greipp P, Billadeau D, Van Ness B, et al. Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial. Blood. 1997;90:340–5.
2. Zandecki M, Bernardi F, Genevieve F, Laï JL, Preudhomme C, Flactif M, et al. Involvement of peripheral blood cells in multiple myeloma: chromosome changes are the rule within circulating plasma cells but not within B lymphocytes. Leukemia. 1997;11:1034–9.
3. Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol. 2001;19:3771–9.
4. Bourhis JH, Bouko Y, Koscielny S, Bakkus M, Greinix H, Derigs G, et al. Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study. Haematologica. 2007;92:1083–90.
5. Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 2015;1:746–54.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献